Biotechnology
Future FinTech Signs Framework Agreement to Acquire TransGen SC Tech Limited Expanding into the Biomedical R&D Sector
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Future FinTech a leading comprehensive financial and digital technology service provider, announced today that on January 7, 2026, its wholly-owned subsidiary, Future FinTech (Hong Kong) Limited ("FTFT HK"), signed a Framework Agreement (the "Agreement"), tha...
2026-01-08 21:15
2149
LumiMind To Showcase Groundbreaking Non-Invasive BCI Technology With Live Gameplay Demo at CES 2026
LAS VEGAS, Jan. 7, 2026 /PRNewswire/ -- LumiMind, a next-generation neurotechnology company pioneering non-invasive, real-time neural modulation, will showcase breakthrough brain–computer interface (BCI) technology atCES 2026 inLas Vegas, including a live, real-time gameplay demonstration develop...
2026-01-08 13:51
134
Arbele Receives FDA Orphan Drug Designation for ARB1002, an Anti-CDH17 Antibody-Drug Conjugate for the Treatment of Pancreatic Cancer
SEATTLE, Jan. 7, 2026 /PRNewswire/ -- Arbele, a biotechnology company focused on developing innovative targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARB1002, its investigational antibody-drug conjugate (ADC...
2026-01-08 00:00
2326
Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update inChina for its internally developed, first-in-class PD-1/VEGF bispecific antibody, ivonescimab. The updated label incorporates final a...
2026-01-07 10:50
3380
Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies
CHENGDU, China, Jan. 6, 2026 /PRNewswire/ -- The 44th J.P. Morgan Healthcare Conference (JPMHC) will be held inSan Francisco, California, USA, from January 12 to 15, 2026. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) has been invited to attend the ...
2026-01-07 10:44
3174
HealthBiome Achieves Dual Regulatory Milestones: FDA NDI Acknowledgment and Korean MFDS Approval for HB05P Muscle Health Ingredient
Akkermansia muciniphila postbiotic receives both U.S. FDA dietary supplement clearance and Korean functional ingredient approval with muscle health claim, positioning HealthBiome for dual-market launch in 2026 DAEJEON, South Korea, Jan. 6, 2026 /PRNewswire/ -- HealthBiome Inc., a pioneering stri...
2026-01-07 08:00
2413
Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference
INCHEON, South Korea, Jan. 6, 2026 /PRNewswire/ -- Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced that Jin-Seok Seo, Chief Executive Officer andHyuk-Jae Lee, Senior Executive Vice President at Celltrion, will present at the 44th Annual J.P. Morgan Healthc...
2026-01-07 07:42
3851
Nuon Medical Unveils Tech-Integrated Packaging Ecosystem at CES 2026, Engineering Clinical Precision into the Point of Skin Contact
LAS VEGAS, Jan. 6, 2026 /PRNewswire/ -- Nuon Medical, a leader in beauty tech
innovation, has announced a comprehensive tech-integrated packaging ecosystem
at CES 2026.
2026-01-07 01:00
185
VivaVision Biotech Receives Positive Written Feedback from FDA - VVN461HD New Drug Application (NDA) Requires Only a "Single Phase III" Pivotal Clinical Study in the U.S. for Non-Infectious Anterior Uveitis Treatment
WENZHOU, China, Jan. 6, 2026 /PRNewswire/ -- Recently, VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced that it has received the written meeting minutes from the U.S. Food and Drug Administration (F...
2026-01-07 00:00
134
Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum
BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today announceddosing of the first patient in the Phase Ib clinical trial of BBT002, a novel platform-in-a...
2026-01-06 22:30
168
Zpeer Launches A-DHA-PT™, a High-Concentration DHA Supplement for Dogs, and Announces Research Collaboration with the University of Tokyo
TOKYO, Jan. 6, 2026 /PRNewswire/ -- Zpeer Inc. (Headquarters: Shibuya, Tokyo; CEO:Toshiya Morino), an animal health company focused on evidence-based therapeutic innovation, has recently announced the launch of A-DHA-PT™ (pronounced "ay-dapt"), a high-concentration DHA supplement designed to supp...
2026-01-06 21:00
192
Xellar and WOOJUNG BIO Announce Multi-Year Strategic Partnership to Advance AI-Enabled Hybrid Human Organ-on-a-Chip (OoC)-Animal Preclinical Platforms
BOSTON and SEOUL, South Korea, Jan. 5, 2026 /PRNewswire/ -- Xellar Biosystems ("Xellar"), a globally leading innovator in next-generation artificial intelligence- and computer vision–assisted, organ-on-a-chip–based drug discovery and development platforms, today announced that it has entered into...
2026-01-06 08:00
2320
Nanjing Delova Announces Statistically Significant and Clinically Meaningful Results From Two Phase 3 Trials of QP-6211 for the Treatment of Postoperative Pain
* Treatment with QP-6211 achieved primary and all key secondary endpoints in both placebo- and active-controlled Phase 3 trials following hemorrhoidectomy or bunionectomy. * QP-6211 demonstrated statistically significant reductions in postoperative pain and opioid consumption through 72 hou...
2026-01-05 23:00
2315
SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a Disease-modifying Therapy for Parkinson's disease
SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI, ATLANTA and NEW HAVEN, Conn. , Jan. 5, 2026 /PRNewswire/ -- SynuSight Biotech ("SynuSight"), a biotechnology company...
2026-01-05 21:05
1193
Earendil Labs Announces Strategic Collaboration with Sanofi to Discover Bispecific Antibodies for Autoimmune Diseases
WILMINGTON, Del., Jan. 5, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with Sanofi to apply Earendil's discovery platform to multiple autoimmune and inflammatory disea...
2026-01-05 18:00
2302
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles into procurement practices and promotes transparency and responsibility ac...
2026-01-05 11:57
2852
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
* Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development. * Under t...
2026-01-05 08:30
3075
ImmunoForge to Host Strategic Partnering Meetings During J.P. Morgan Healthcare Conference 2026
* Focusing on global out-licensing of Phase 2 assets PF1801 and PF1804. * Company to engage with global big pharma in San Francisco to accelerate U.S. clinical entry. SEOUL, South Korea, Jan. 1, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd. (Co-CEOs Sung-Min Ahn and Kiho Chang), a clinical-stage ...
2026-01-01 14:00
1230
Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring
SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal antibody (R&D code: 9MW3811) for pathological scar...
2025-12-30 22:00
5269
Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO
HONG KONG, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, becoming the first AI-driven biotech company to go public ...
2025-12-30 17:00
12362
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 321 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Tower Capital Asia announces majority investment in V-Key - a leader in digital identity and mobile application security
[Picked up by 265 media titles]
2026-02-13 01:52
Appier Delivers Record Results Driven by Agentic AI Innovation
[Picked up by 263 media titles]
2026-02-13 17:03Most Read
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
8443
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
7600
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
7150
